di-tert-butyl 2-[(tert-butoxyphosphinyl)methyl]pentane-1,5-dioate | 229472-54-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: di-tert-butyl 2-[(tert-butoxyphosphinyl)methyl]pentane-1,5-dioate
• 英文别名: di-tert-butyl 2{[(tert-butoxy)phosphoryl]methyl}pentane-1,5-dioate；Di-tert-butyl 2-[(tert-butoxyphosphinyl)methyl]-pentanedioate；Di-tert-butyl 2-[(tert-butoxyphosphinyl)methyl]pentanedioate
• CAS: 229472-54-2
• 化学式: C₁₈H₃₅O₆P
• 分子量: 378.446
• InChiKey: BATVLUUHUPBPJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.36
• 重原子数：
  25.0
• 可旋转键数：
  7.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  78.9
• 氢给体数：
  0.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  di-tert-butyl 2-[(tert-butoxyphosphinyl)methyl]pentane-1,5-dioate 在 三氟乙酸 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 32.0h， 生成 2-[({[phenylamino]methyl}(hydroxy-phosphinyl))-methyl]pentanedioic acid
  参考文献：
  名称：

  Design and Pharmacological Activity of Phosphinic Acid Based NAALADase Inhibitors

  摘要：

  A novel series of phosphinic acid based inhibitors of the neuropeptidase NAALADase are described in this work. This series of compounds is the most potent series of inhibitors of the enzyme described to date. In addition, we have shown that these compounds are protective in animal models of neurodegeneration. Compound 34 significantly prevented neurodegeneration in a middle cerebral artery occlusion model of cerebral ischemia. In addition, in the chronic constrictive mc del of neuropathic pain, compound 34 significantly attenuated the hypersensitivity observed with saline-treated animals. These data suggest that NAALADase inhibition may provide a new approach for the treatment of both neurodegenerative disorders and peripheral neuropathies.

  DOI：

  10.1021/jm0001774
• 作为产物：
  描述：

  丙烯酸叔丁酯 在 六甲基磷酰三胺 、 4-二甲氨基吡啶 、 ammonium hypophosphite 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 六甲基二硅氮烷 作用下， 以 二氯甲烷 为溶剂， 生成 di-tert-butyl 2-[(tert-butoxyphosphinyl)methyl]pentane-1,5-dioate
  参考文献：
  名称：

  Design and Pharmacological Activity of Phosphinic Acid Based NAALADase Inhibitors

  摘要：

  A novel series of phosphinic acid based inhibitors of the neuropeptidase NAALADase are described in this work. This series of compounds is the most potent series of inhibitors of the enzyme described to date. In addition, we have shown that these compounds are protective in animal models of neurodegeneration. Compound 34 significantly prevented neurodegeneration in a middle cerebral artery occlusion model of cerebral ischemia. In addition, in the chronic constrictive mc del of neuropathic pain, compound 34 significantly attenuated the hypersensitivity observed with saline-treated animals. These data suggest that NAALADase inhibition may provide a new approach for the treatment of both neurodegenerative disorders and peripheral neuropathies.

  DOI：

  10.1021/jm0001774

文献信息

• Pharmaceutical compositions and methods for treating anxiety, anxiety disorders and memory impairment using NAALADase inhibitors
  申请人：——

  公开号：US20030013687A1

  公开（公告）日：2003-01-16

  The present invention relates to pharmaceutical compositions and methods of using NAALADase inhibitors for treating glutamate-mediated diseases, disorders and conditions selected from the group consisting of anxiety, anxiety disorders and memory impairment.

  本发明涉及制药组合物及使用NAALADase抑制剂治疗由谷氨酸介导的疾病、疾病和病状的方法，所述疾病、疾病和病状包括焦虑、焦虑症和记忆障碍。
• Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors
  申请人：——

  公开号：US20030064912A1

  公开（公告）日：2003-04-03

  The present disclosure relates to a method of inhibiting angiogenesis comprising administering a N-Acetylated &agr;-Linked Acidic Dipeptidase (NAALADase) inhibitor to a patient in need thereof, and a pharmaceutical composition comprising an anti-angiogenic effective amount of a NAALADase inhibitor and a pharmaceutically acceptable carrier.

  本公开涉及一种抑制血管生成的方法，包括向需要该方法的患者给予N-乙酰化的α-连接酸性二肽酶（NAALADase）抑制剂，以及包含抗血管生成有效量的NAALADase抑制剂和药用载体的制药组合物。
• NAALADase inhibitors useful as pharmaceutical compounds and compositions
  申请人：——

  公开号：US20030083374A1

  公开（公告）日：2003-05-01

  The present invention relates to N-Acetylated &agr;-Linked Acidic Dipeptidase (NAALADase) inhibitors enzyme activity, pharmaceutical compositions comprising such inhibitors, and methods of their use to inhibit NAALADase enzyme activity, thereby effecting neuronal activities, inhibiting angiogenesis, and treating glutamate abnormalities, compulsive disorders, prostate diseases, pain and diabetic neuropathy.

  本发明涉及N-乙酰化的α-连接酸性二肽酶（NAALADase）抑制剂酶活性，包含这些抑制剂的制药组合物，以及使用它们抑制NAALADase酶活性的方法，从而影响神经活动，抑制血管生成，治疗谷氨酸异常、强迫性障碍、前列腺疾病、疼痛和糖尿病神经病变。
• Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
  申请人：Guilford Pharmaceuticals Inc.

  公开号：US06395718B1

  公开（公告）日：2002-05-28

  The present disclosure relates to a method of inhibiting angiogenesis comprising administering a N-Acetylated &agr;-Linked Acidic Dipeptidase (NAALADase) inhibitor to a patient in need thereof, and a pharmaceutical composition comprising an anti-angiogenic effective amount of a NAALADase inhibitor and a pharmaceutically acceptable carrier.

  本公开涉及一种抑制血管生成的方法，包括向需要该方法的患者施用N-乙酰化的α-链接酸性二肽酶（NAALADase）抑制剂，以及包含抗血管生成有效量的NAALADase抑制剂和药学上可接受的载体的药物组合物。
• Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors
  申请人：Guilford Pharmaceuticals Inc.

  公开号：US06228888B1

  公开（公告）日：2001-05-08

  The present invention relates to methods of using NAALADase inhibitors for treating glutamate-mediated diseases, disorders and conditions selected from the group consisting of anxiety, anxiety disorders and memory impairment.

  本发明涉及使用NAALADase抑制剂治疗由谷氨酸介导的疾病、障碍和症状的方法，所述疾病、障碍和症状包括焦虑、焦虑障碍和记忆障碍。